Programs for Assessment of Technology in Health-PATH, Research Institute-St Joseph's Healthcare, Hamilton, Ontario, Canada.
J Am Med Inform Assoc. 2012 May-Jun;19(3):423-38. doi: 10.1136/amiajnl-2011-000310. Epub 2011 Oct 7.
To conduct a systematic review and synthesis of the evidence surrounding the cost-effectiveness of health information technology (HIT) in the medication process.
Peer-reviewed electronic databases and gray literature were searched to identify studies on HIT used to assist in the medication management process. Articles including an economic component were reviewed for further screening. For this review, full cost-effectiveness analyses, cost-utility analyses and cost-benefit analyses, as well as cost analyses, were eligible for inclusion and synthesis.
The 31 studies included were heterogeneous with respect to the HIT evaluated, setting, and economic methods used. Thus the data could not be synthesized, and a narrative review was conducted. Most studies evaluated computer decision support systems in hospital settings in the USA, and only five of the studied performed full economic evaluations.
Most studies merely provided cost data; however, useful economic data involves far more input. A full economic evaluation includes a full enumeration of the costs, synthesized with the outcomes of the intervention.
The quality of the economic literature in this area is poor. A few studies found that HIT may offer cost advantages despite their increased acquisition costs. However, given the uncertainty that surrounds the costs and outcomes data, and limited study designs, it is difficult to reach any definitive conclusion as to whether the additional costs and benefits represent value for money. Sophisticated concurrent prospective economic evaluations need to be conducted to address whether HIT interventions in the medication management process are cost-effective.
对围绕医疗信息技术(HIT)在药物治疗过程中的成本效益的证据进行系统评价和综合分析。
检索同行评议的电子数据库和灰色文献,以确定用于协助药物管理过程的 HIT 研究。对包括经济组成部分的文章进行了进一步筛选。在本次综述中,纳入并综合了全成本效益分析、成本效用分析和成本效益分析以及成本分析。
纳入的 31 项研究在评估的 HIT、设置和经济方法方面存在异质性。因此,无法对数据进行综合,故进行了叙述性综述。大多数研究评估了美国医院环境中的计算机决策支持系统,只有五项研究进行了全面的经济评估。
大多数研究仅提供了成本数据;然而,有用的经济数据需要更多的投入。全面的经济评估包括对干预结果进行全面成本枚举。
该领域的经济文献质量较差。少数研究发现,尽管 HIT 的购置成本增加,但它可能具有成本优势。然而,由于成本和结果数据的不确定性以及有限的研究设计,很难得出关于额外成本和收益是否代表物有所值的明确结论。需要进行复杂的同期前瞻性经济评估,以确定药物管理过程中的 HIT 干预是否具有成本效益。